Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.63 |
| ▸ | METAP1 | P53582 | 4/20 | 0.59 |
| ▸ | HTR2C | P28335 | 3/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528990 | 0.95 | ACHE (0.62) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL8556555 | 0.94 | ACHE (0.60) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL9324677 | 0.90 | METAP1 (0.63) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL8756180 | 0.84 | CYP19A1 (0.58) | ACHEMETAP1HTR2CHTR1ACYP19A1 | |
| SCHEMBL866816 | 0.82 | METAP1 (0.67) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL677676 | 0.82 | ACHE (0.58) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL5951441 | 0.81 | ACHE (0.45) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL30641036 | 0.81 | ACHE (0.54) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL3866934 | 0.80 | ACHE (0.45) | ACHEMETAP1HTR2CDRD3HTR2A | |
| SCHEMBL14019342 | 0.80 | METAP1 (0.61) | ACHEMETAP1HTR2CDRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1329365-C | Indanes and indanones and their use in perfumery | GIVAUDAN SA (CH) | 2007-08-01 | — | — | CN | claimed |
| CN-1615294-A | Indanes and indanones and their use in perfumery | GIVAUDAN SA (CH) | 2005-05-11 | — | — | CN | claimed |
| CN-116082131-B | Method for synthesizing 1-indanone compound by one-pot method | 苏州华道生物药业股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-116082131-A | Method for synthesizing 1-indanone compound by one-pot method | 苏州华道生物药业股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3820939-A1 | HETEROPHASIC POLYPROPYLENE COMPOSITION WITH IMPROVED BALANCE OF PROPERTIES | Borealis AG (AT) | 2021-05-19 | — | — | EP | disclosed |
| EP-3814388-A1 | CATALYSTS | Borealis AG (AT) | 2021-05-05 | — | — | EP | disclosed |
| WO-2020011825-A1 | HETEROPHASIC POLYPROPYLENE COMPOSITION WITH IMPROVED BALANCE OF PROPERTIES | BOREALIS AG (AT) | 2020-01-16 | — | — | WO | disclosed |
| WO-2019052820-A1 | POLYPROPYLENE COMPOSITION | BOREALIS AG (AT) | 2019-03-21 | — | — | WO | disclosed |
| EP-3131934-A2 | IMPROVED CATALYST SYSTEM FOR PRODUCING POLYETHYLENE COPOLYMERS IN A HIGH TEMPERATURE SOLUTION POLYMERIZATION PROCESS | Borealis AG (AT) | 2017-02-22 | — | — | EP | disclosed |
| CN-105001206-A | Inhibitors of Bruton's Tyrosine Kinase | HOFFMANN LA ROCHE | 2015-10-28 | — | — | CN | disclosed |
| WO-2015158790-A2 | IMPROVED CATALYST SYSTEM FOR PRODUCING POLYETHYLENE COPOLYMERS IN A HIGH TEMPERATURE SOLUTION POLYMERIZATION PROCESS | BOREALIS AG (AT) | 2015-10-22 | — | — | WO | disclosed |
| US-20030009033-A1 | Substituted condensation products of N-benzyl-3-indenylacent amides with heterocyclic aldehydes for neoplasia | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6479493-B1 | INHIBITING PHOSPHODIESTERASE 2 IN THE DISEASED TISSUE, WITHOUT SUBSTANTIALLY INHIBITING CYCLOOXYGENASES I AND II, THEREBY CAUSING MACROPHAGE APOPTOSIS | CELL PATHWAYS, INC. | 2002-11-12 | — | — | US | disclosed |
| US-6465494-B1 | PHOSPHODIESTERASE 2 AND 5 INHIBITORS; DOES NOT SUBSTANTIALLY INHIBIT COX I OR II; INDUCING APOPTOSIS IN PULMONARY MACROPHAGES THAT GENERATE LUNG DAMAGING METABOLITES AND LEUKOTRIENE B4 | CELL PATHWAYS, INC. | 2002-10-15 | — | — | US | disclosed |
| WO-2002067936-A1 | METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | CELL PATHWAYS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| US-6426349-B1 | ADMINISTERING (Z)-5-FLUORO-2-METHYL-(4-PYRIDYLIDENE)-3-(N-BENZYL) INDENYLACETAMIDE HYDROCHLORIDE; REGULATING APOPTOSIS | CELL PATHWAY AND THE UNIVERSITY OF ARIZONA | 2002-07-30 | — | — | US | disclosed |
| US-6166053-A | Substituted condensation products of N-benzyl-3-idenylacetamides with heterocyclic aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6066634-A | PHOSPHODIESTERASE INHIBITOR | CELL PATHWAYS, INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-6028116-A | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-22 | — | — | US | disclosed |
| US-5948779-A | APOPTOSIS; ANTICANCER AGENT | CELL PATHWAYS, INC. (US) | 1999-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030009033-A1 | Substituted condensation products of N-benzyl-3-indenylacent amides with heterocyclic aldehydes for neoplasia | ACIN1, AOX1, CCAR2 | ACHE 4144/4885METAP1 2044/4885HTR2C 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.